A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (NCT06018337)
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Who can join: Review the eligibility criteria below.
Location: Research Site 1141-0 — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (258 Sites)
Showing the first 25 of 258 sites.
- Research Site 1141-0 — Tucson, Arizona
- Research Site 1114-0 — Fullerton, California
- Research Site 1107-0 — Los Angeles, California
- Research Site 1118-0 — Orange, California
- Research Site 1143-0 — Sacramento, California
- Research Site 1132-0 — Santa Barbara, California
- Research Site 1137-0 — Aurora, Colorado
- Research Site 1129-0 — Lone Tree, Colorado
- Research Site 1154-0 — Jacksonville, Florida
- Research Site 1145-0 — Miami, Florida
- Research Site 1150-0 — Orange City, Florida
- Research Site 1125-0 — Palm Bay, Florida
- Research Site 1155-0 — Athens, Georgia
- Research Site 1110-0 — Savannah, Georgia
- Research Site 1147-0 — Chicago, Illinois
- Research Site 1124-0 — Chicago Ridge, Illinois
- Research Site 1152-0 — Fort Wayne, Indiana
- Research Site 1106-0 — Merriam, Kansas
- Research Site 1104-0 — Louisville, Kentucky
- Research Site 1122-0 — Silver Spring, Maryland
- Research Site 8639-0 — Silver Spring, Maryland
- Research Site 1109-0 — Kansas City, Missouri
- Research Site 1158-0 — Camden, New Jersey
- Research Site 1111-0 — Florham Park, New Jersey
- Research Site 1157-0 — Sante Fe, New Mexico
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Breast Cancer
- Assessing the Time Demands of Cancer — Birmingham, Alabama
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — Commack, New York
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Tucson, Arizona
- Roll-over Study to Allow Continued Access to Ribociclib — Chandler, Arizona
Explore by condition: All Metastatic Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.